Patterns of early and delayed visual response to ranibizumab treatment for neovascular age-related macular degeneration

JAMA Ophthalmology

Volumn 134, Issue 5, 2016, Pages 545-553

  Stoller, Glenn L ^a   Kokame, Gregg T ^b,c   Dreyer, Richard F ^d   Shapiro, Howard ^e   Tuomi, Lisa L ^e  

^a OPHTHALMIC CONSULTANTS OF LONG ISLAND   (United States)

^b Retina Center at Pali Momi   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d Retina Northwest   (United States)

^e GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; ARTICLE; CENTRAL FOVEAL THICKNESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VISION; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; FEMALE; INTRAVITREAL DRUG ADMINISTRATION; MALE; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; WET MACULAR DEGENERATION;

AGED; ANGIOGENESIS INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; RANIBIZUMAB; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84968912308     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2016.0379     Document Type: Article

References (16)

1. Brown DM, Kaiser PK, MichelsM, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
2. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
3. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-relatedmacular degeneration: PIER study year 1. Am J Ophthalmol. 2008;145(2):239-248.
4. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular dege neration. Ophthalmology. 2009;116(9):1731-1739.
5. Brown DM, MichelsM, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therap y for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65.e5.
6. Martin DFMaguire MG Ying GS Grunwald JE Fine SL Jaffe GJ; CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 364 20 1897-1908
7. Chakravarthy U, Harding SP, Rogers CA, et al; IVAN Study Investigators. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7): 1399-1411.
8. Heier JS, Brown DM, Chong V, et al; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548.
9. Martin DF,Maguire MG, Fine SL, et al; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology. 2012;119(7):1388-1398.
10. Busbee BG, Ho AC, Brown DM, et al; HARBOR Study Group. Twelve-month efficacy and safety of 0.5mg or 2.0mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046-1056.
11. Chakravarthy U, Harding SP, Rogers CA, et al; IVAN Study Investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382 (9900):1258-1267.
12. Ho AC, Busbee BG, Regillo CD, et al; HARBOR Study Group. Twenty-four-month efficacy and safety of 0.5mg or 2.0mg ranibizu mab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121(11):2181-2192.
13. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: Ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121 (1):193-201.
14. Chong V. Ranibizumab for the treatment of wet AMD: A summary of real-world studies. Eye (Lond). 2016;30(2):270-286.
15. Browning DJ, Glassman AR, Aiello LP, et al; Diabetic Retinopathy Clinical Research Network. Optical coherence tomography measurements and analysismethods in optical coherence tomography studies of diabetic macular edema. Ophthalmology. 2008;115(8):1366- 1371, 1371.e1.
16. Hariprasad SM, Morse LS, Shapiro H,Wong P, Tuomi L. Fixed monthly versus less frequent ranibizumab dosing and predictors of visual response in exudative age-related macular degeneration. J Ophthalmol. 2012;2012:690641.